Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 13, 2026
TickeronGET DAILY SIGNALS
AXNX and TCRT: Contrasting Paths in Healthcare – Acquisition Success vs. Strategic Pivot

AXNX and TCRT: Contrasting Paths in Healthcare – Acquisition Success vs. Strategic Pivot

Key Takeaways

  • AXNX (Axonics) was acquired by Boston Scientific in a $3.7 billion cash deal and is no longer an independently traded public company.
  • TCRT (Alaunos Therapeutics) remains a publicly listed, pre-revenue biotechnology company now refocusing on preclinical obesity and metabolic drug development.
  • The two names sit at opposite ends of the risk spectrum: a matured, acquired medical-device leader versus an early-stage, cash-constrained biotech exploring strategic alternatives.
  • Alaunos has relied on recent equity raises and carries a micro-cap valuation, reflecting ongoing operating losses and limited cash runway.
  • Relative performance and market positioning are not directly comparable because Axonics no longer trades, making historical context essential for investors reviewing this pairing.

Why Compare These Two Stocks?

Comparing AXNX and TCRT offers a useful lens on two very different phases of the corporate lifecycle. Axonics built a commercially successful medical-device franchise before being acquired, while Alaunos Therapeutics is a small biotechnology company navigating a strategic pivot with limited capital. This stock comparison may appeal to traders evaluating relative performance and market positioning across healthcare subsectors, as well as to investors studying how corporate events such as acquisitions and strategic reprioritizations reshape a security's risk and return profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Axonics' Journey to Acquisition

AXNX refers to Axonics, Inc., a medical technology company that developed implantable sacral neuromodulation (SNM) systems used to treat bladder and bowel dysfunction, along with a urethral bulking agent for stress urinary incontinence. The company generated strong revenue growth in its final independent reporting periods, reflecting higher utilization at existing accounts and the addition of new customers.

The defining event for Axonics was its acquisition by Boston Scientific, announced in early 2024 and completed in November 2024 for $71 per share in cash, representing an equity value of approximately $3.7 billion. Following the closing, Axonics' shares were delisted from the Nasdaq, and the company now operates within Boston Scientific's urology portfolio. For investors, this means AXNX is no longer available as a standalone public security; any discussion of recent market activity refers to the period leading up to the transaction's completion. From what I see, this outcome highlights how successful commercial execution can lead to a clean exit for shareholders.

Alaunos' Current Position and Challenges

TCRT is the ticker for Alaunos Therapeutics, Inc., formerly known as Ziopharm Oncology. The company has historically been an oncology-focused cell therapy developer but has shifted toward a preclinical obesity and metabolic health program built around a small-molecule candidate intended to avoid the hormonal manipulation common to many existing treatments. In parallel, management has stated it is exploring strategic alternatives, including an acquisition, merger, reverse merger, sale of assets, partnerships, or capital raises.

In recent market activity, Alaunos has reflected the pressures typical of a pre-revenue biotech. The company completed registered direct offerings to raise working capital, and regulatory filings have described limited cash resources and ongoing net losses. A dispute with the University of Texas M.D. Anderson Cancer Center over unpaid invoices was settled in late 2025 for roughly $285,000, removing a legal overhang. These developments underscore a constrained balance sheet and an evolving business focus that continue to shape sentiment around the stock. I’m watching this closely as the company moves forward with its new direction.

Comparing the Two Companies

The most fundamental contrast between these two securities is their status as investable assets. AXNX was a profitable, revenue-generating medical-device company that ultimately exited the public market through a cash acquisition, delivering a defined outcome to shareholders. TCRT remains actively traded but is pre-revenue, loss-making, and dependent on raising additional financing to sustain operations.

The companies also differ sharply in sector exposure and risk factors. Axonics operated in commercial-stage medtech with established regulatory approvals and growing adoption. Alaunos operates in early-stage biotech, where value hinges on preclinical validation, future financing, and strategic transactions rather than recurring sales. Consequently, growth drivers, momentum, and market sentiment are structurally different: Axonics was anchored by fundamentals and an acquisition catalyst, while Alaunos is driven by restructuring news, capital raises, and program announcements. One thing that stands out is how these profiles appeal to very different investor types.

AI Insights on the Pairing

Based on observable factors, Tickeron's AI would likely view these two names through very different lenses. A stock that has been acquired and delisted offers no forward-looking tradable trend, so AXNX would hold limited current appeal for an AI trading system seeking actionable price signals. In contrast, TCRT presents a live, high-volatility, event-driven profile that may attract momentum or mean-reversion strategies, though its thin capitalization and uncertain fundamentals introduce meaningful risk. Probabilistically, the AI would favor the actively traded security, but its engagement with TCRT would depend heavily on trend consistency, stability, and the durability of any emerging catalyst.

Using Tickeron’s AI Trading Bots for Research

In my own analysis, I often turn to Tickeron’s AI tools to cross-check market signals and bot performance across volatile names like these. The platform’s library of automated strategies helps put current conditions into perspective without replacing core fundamental review. It’s a practical way to stay informed on event-driven opportunities while keeping risk parameters in view.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TCRT, AXNX

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


TCRT in +7.50% Uptrend, advancing for three consecutive days on November 18, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TCRT advanced for three days, in 182 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 72 cases where TCRT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

TCRT moved above its 50-day moving average on November 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for TCRT moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRT as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TCRT turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 10-day moving average for TCRT crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TCRT entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.780) is normal, around the industry mean (3.596). P/E Ratio (-0.994) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a cancer treatment company

Industry Biotechnology

Industry
Biotechnology
Address
501 East Las Olas Boulevard
Phone
+1 346 355-4099
Employees
1
Web
https://www.alaunos.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.